The metabolic syndrome and endothelial dysfunction: Common highway to type 2 diabetes and CVD?

被引：49

作者：

Diamant M. ^{[1
]}

Tushuizen M.E. ^{[1
]}

机构：

[1] Department of Endoncrinology, Diabetes Center, VU University Medical Center, 1007 MB Amsterdam

来源：

Current Diabetes Reports | 2006年 / 6卷 / 4期

关键词：

Insulin Resistance; Metabolic Syndrome; Metformin; Endothelial Dysfunction; Pioglitazone;

D O I：

10.1007/s11892-006-0061-4

中图分类号：

学科分类号：

摘要：

Due to global lifestyle changes, obesity (the main driver of type 2 diabetes [T2D] and cardiovascular disease [CVD]) is reaching pandemic proportions. The metabolic syndrome, which is regarded as a prediabetic state, is characterized by a concurrence of interrelated cardiovascular risk factors, including abdominal obesity, insulin resistance, hypertension, dyslipidemia, and glucose intolerance. Endothelial dysfunction (ED) is common in the metabolic syndrome and is associated with increased risk for T2D and CVD. This review focuses on the mechanisms linking ED to the metabolic syndrome, T2D, and CVD, and the possible therapies that may improve ED and reduce T2D and CVD risk. Copyright © 2006 by Current Science Inc.

引用

页码：279 / 286

页数：7

共 77 条

[51]

Yki-Jarvinen H., Insulin resistance and endothelial dysfunction, Best Pract Res Clin Endocrinol Metab, 17, pp. 411-430, (2003)

[52]

Lonn E., Bosch J., Yusuf S., Et al., Effects of long-term vitamin E supplementation on cardiovascular events and cancer: A randomized controlled trial, JAMA, 293, pp. 1338-1347, (2005)

[53]

MRC/BHF Heart Protection Study of antioxidant vitamin supplementation in 20,536 high-risk individuals: A randomised placebo-controlled trial, Lancet, 360, pp. 23-33, (2002)

[54]

Lonn E., Yusuf S., Arnold M.J., Et al., Homocysteine lowering with folic acid and B vitamins in vascular disease, N Engl J Med, 354, pp. 1567-1577, (2006)

[55]

Bonaa K.H., Njolstad I., Ueland P.M., Et al., Homocysteine lowering and cardiovascular events after acute myocardial infarction, N Engl J Med, 354, pp. 1578-1588, (2006)

[56]

Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34), Lancet, 352, pp. 854-865, (1998)

[57]

Zhou G., Myers R., Li Y., Et al., Role of AMP-activated protein kinase in mechanism of metformin action, J Clin Invest, 108, pp. 1167-1174, (2001)

[58]

Kukidome D., Nishikawa T., Sonoda K., Et al., Activation of AMP-activated protein kinase reduces hyperglycemia-induced mitochondrial ROS production and promotes mitochondrial biogenesis in human umbilical vein endothelial cells, Diabetes, 55, pp. 120-127, (2006)

[59]

Davis B.J., Xie Z., Viollet B., Zou M.H., Activation of the AMP-activated kinase by antidiabetes drug metformin stimulates nitric oxide synthesis in vivo by promoting the association of heat shock protein 90 and endothelial nitric oxide synthase, Diabetes, 55, pp. 496-505, (2006)

[60]

Caballero A.E., Delgado A., Aguilar-Salinas C.A., Et al., The differential effects of metformin on markers of endothelial activation and inflammation in subjects with impaired glucose tolerance: A placebo-controlled, randomized clinical trial, J Clin Endocrinol Metab, 89, pp. 3943-3948, (2004)

← 1 2 3 4 5 6 7 8 →